Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 1073-1084

  Kryeziu, Kushtrim ^a,b,c   Jungwirth, Ute ^a,b,c   Hoda, Mir Alireza ^a,b   Ferk, Franziska ^a,b   Knasmüller, Siegfried ^a,b   Karnthaler Benbakka, Claudia ^c   Kowol, Christian R ^c   Berger, Walter ^a,b,c   Heffeter, Petra ^a,b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BRCA1 PROTEIN; ERLOTINIB; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROTECTION; COMET ASSAY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; M PHASE CELL CYCLE CHECKPOINT; MESOTHELIOMA; MULTIPLE CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ARSENICALS; BRCA1 PROTEIN; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; OXIDES; PHOSPHORYLATION; QUINAZOLINES; RAD51 RECOMBINASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879290247     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0065     Document Type: Article

References (50)

1. Jungwirth U, Kowol CR, Keppler BK, Hartinger CG, Berger W, Heffeter P. Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal 2011;15:1085-127.
2. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepato-cellular carcinoma cell lines. Biochem Biophys Res Commun 2002;291:861-7.
3. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
4. Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanisms of action. Semin Hematol 2002;39:3-7.
5. Emadi A, Gore SD. Arsenic trioxide - an old drug rediscovered. Blood Rev 2010;24:191-9.
6. Takahashi S. Combination therapy with arsenic trioxide for hemato-logical malignancies. Anticancer Agents Med Chem 2010;10:504-10.
7. Zhang X, Su Y, Zhang M, Sun Z. Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo. Cancer Lett 2012;318:93-8.
8. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 2007;25:77-84.
9. Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 2002;20:327-30.
10. Kim KB, Bedikian AY, Camacho LH, Papadopoulos NE, McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer 2005;104:1687-92.
11. Kindler HL, Aklilu M, Nattam S, Vokes EE. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol 2008;31:553-6.
12. Subbarayan PR, Lima M, Ardalan B. Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 2007;46:557-61.
13. Chervona Y, Arita A, Costa M. Carcinogenic metals and the epigenome: understanding the effect of nickel, arsenic, and chromium. Metallomics 2012;4:619-27.
14. Eblin K. Potential clinical significance of EGFR-mediated signaling following inorganic arsenic exposure in human lung. Toxicol Sci 2009;109:169-71.
15. Carpenter RL, Jiang BH. Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer. Curr Cancer Drug Targets 2013 Jan 2. [Epub ahead of print].
16. Simeonova PP, Wang S, Hulderman T, Luster MI. c-Src-dependent activation of the epidermal growth factor receptor and mitogen-acti-vated protein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 2002;277:2945-50.
17. Kodigepalli KM, Dutta PS, Bauckman KA, Nanjundan M. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells. FEBS Lett 2012;587:5-16.
18. 3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Cell Signal 2006;18:244-55.
19. Andrew AS, Mason RA, Memoli V, Duell EJ. Arsenic activates EGFR pathway signaling in the lung. Toxicol Sci 2009;109:350-7.
20. Tseng HY, Liu ZM, Huang HS. NADPH oxidase-produced superoxide mediates EGFR transactivation by c-Src in arsenic trioxide-stimulated human keratinocytes. Arch Toxicol 2012;86:935-45.
21. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermalgrowth factorreceptor: fromdevelopment to tumorigenesis. Differentiation 2007;75:770-87.
22. Myllynen L, Rieckmann T, Dahm-Daphi J, Kasten-Pisula U, Petersen C, Dikomey E, et al. In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. Radiother Oncol 2011;101:147-51.
23. Gazdar AF. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 2010;29:37-48.
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
25. Berger W, Elbling L, Minai-Pour M, Vetterlein M, Pirker R, Kokoschka EM, et al. Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. Int J Cancer 1994;59:717-23.
26. Heffeter P, Pirker C, Kowol CR, Herrman G, Dornetshuber R, Miklos W, et al. Impact of terminal dimethylation on the resistance profile of alpha-N-heterocyclic thiosemicarbazones. Biochem Pharmacol 2012;83:1623-33.
27. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000;35:206-21.
28. Heffeter P, Popovic-Bijelic A, Saiko P, Dornetshuber R, Jungwirth U, Voevodskaya N, et al. Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772). Curr Cancer Drug Targets 2009;9:595-607.
29. Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M, et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol 2011;6:852-63.
30. Liu ZM, Tseng JT, Hong DY, Huang HS. Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. Biochem J 2011;438:349-58.
31. 3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol 2002;21:49-55.
32. Chao JI, Hsu SH, Tsou TC. Depletion of securin increases arsenite-induced chromosome instability and apoptosis via a p53-independent pathway. Toxicol Sci 2006;90:73-86.
33. Seol JG, Park WH, Kim ES, Jung CW, Hyun JM, Kim BK, et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 1999;265:400-4.
34. Kriegs M, Kasten-Pisula U, Rieckmann T, Holst K, Saker J, Dahm-Daphi J, et al. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst) 2010;9:889-97.
35. Mukherjee B, Choy H, Nirodi C, Burma S. Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization. Semin Radiat Oncol 2010;20:250-7.
36. Toulany M, Lee KJ, Fattah KR, Lin YF, Fehrenbacher B, Schaller M, et al. Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res 2012;10:945-57.
37. Li L, Wang H, Yang ES, Arteaga CL, Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 2008;68:9141-6.
38. Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, et al. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat 2008;11:1-16.
39. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-92.
40. Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, et al. Evaluation of arsenic trioxide by the pediatric pre-clinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer 2012;59:753-5.
41. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
42. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011;75:50-83.
43. Hartwig A. Metal interaction with redox regulation: an integrating concept in metal carcinogenesis? Free Radic Biol Med 2012;55C: 63-72.
44. Herbert KJ, Snow ET. Modulation of arsenic-induced epidermal growth factor receptor pathway signalling by resveratrol. Chem Biol Interact 2012;198:38-48.
45. Ivanov VN, Hei TK. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene 2005;24: 616-26.
46. 3)-induced differentiation of acute promyelocytic leukemia cell line. Leuk Res 2010;34:1501-5.
47. Martinez VD, Vucic EA, Adonis M, Gil L, Lam WL. Arsenic biotransformation as a cancer promoting factor by inducing DNA damage and disruption of repair mechanisms. Mol Biol Int 2011;2011: 718974.
48. Jungwirth U, Kowol CR, Hartinger C, Keppler BK, Berger W, Heffeter P. Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal 2011;15:1085-127.
49. Andrew AS, Karagas MR, Hamilton JW. Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water. Int J Cancer 2003;104:263-8.
50. Ying S, Myers K, Bottomley S, Helleday T, Bryant HE. BRCA2-dependent homologous recombination is required for repair of arsenite-induced replication lesions in mammalian cells. Nucleic Acids Res 2009;37:5105-13.